

Conatumumab

Cat. No.:	HY-P99260
CAS No.:	896731-82-1
Target:	TNF Receptor
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) (K_d : 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. ^{[1][2][3]} .								
IC₅₀ & Target	IC50: DR5 (<1 nM) ^[2]								
In Vitro	<p>Conatumumab (0-10 μg/mL, 4 h) activates caspase-3/7 in Colo205, H-2122, and MiaPaCa2 cells^[2]. Conatumumab (0-10 μg/mL, 24 h) reduces cell viability in sensitive tumor cell lines (Colo205, H-2122, and MiaPaCa2 cells)^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Viability Assay^[2]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Colo205, H-2122, and MiaPaCa2 cells</td> </tr> <tr> <td>Concentration:</td> <td>0-10 μg/mL</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently inhibited cell viability.</td> </tr> </table>	Cell Line:	Colo205, H-2122, and MiaPaCa2 cells	Concentration:	0-10 μ g/mL	Incubation Time:	24 h	Result:	Dose-dependently inhibited cell viability.
Cell Line:	Colo205, H-2122, and MiaPaCa2 cells								
Concentration:	0-10 μ g/mL								
Incubation Time:	24 h								
Result:	Dose-dependently inhibited cell viability.								
In Vivo	<p>Conatumumab (0-100 μg, i.p., twice weekly) inhibits tumor growth in mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors^[2]. Conatumumab (2.5 μg, i.p., three times per week) enhances the antitumor activity of chemotherapeutics (CPT11, HY-16562) (80 mg/kg) in Colo 205 xenograft^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors^[2]</td> </tr> <tr> <td>Dosage:</td> <td>0, 0.1, 0.3, 1, 3, 10, 30, 100 μg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection (i.p.), twice weekly.</td> </tr> <tr> <td>Result:</td> <td>Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC).</td> </tr> </table>	Animal Model:	Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors ^[2]	Dosage:	0, 0.1, 0.3, 1, 3, 10, 30, 100 μ g	Administration:	Intraperitoneal injection (i.p.), twice weekly.	Result:	Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC).
Animal Model:	Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors ^[2]								
Dosage:	0, 0.1, 0.3, 1, 3, 10, 30, 100 μ g								
Administration:	Intraperitoneal injection (i.p.), twice weekly.								
Result:	Dose-dependently inhibited tumor growth. Induced caspase-3 activation in tumors (determined by IHC).								

REFERENCES

- [1]. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91.
- [2]. Kaplan-Lefko PJ, et al. Conatumumab, a fully human agonist antibody to death receptor 5, induces apoptosis via caspase activation in multiple tumor types. Cancer Biol Ther. 2010 Apr 15;9(8):618-31.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA